D-1841-2019 Class III Terminated

Recalled by Akorn, Inc. — Lake Forest, IL

FDA drug recall D-1841-2019 was initiated by Akorn, Inc. on Aug 6, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid. The recall status is terminated (terminated Jul 28, 2022). Affected quantity: 8187 vials.

Recall details

Product Type
Drugs
Report Date
Sep 4, 2019
Initiation Date
Aug 6, 2019
Termination Date
Jul 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8187 vials

Product description

Eptifibatide Injection, a) 20 mg/10 mL (2 mg/mL),10 mL Single Use Vial, NDC 17478-902-10, b) 200 mg/100 mL (2 mg/mL), 100 mL Single-use Vial, NDC 17478-902-90, For Intravenous Use Only, Rx Only, Manufactured by: Akorn Inc., Lake Forest, IL 60045.

Reason for recall

Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.

Distribution pattern

Nationwide in the U.S.

Code information

Lot #s: a) 091307A, Exp. 9/19; 101097A, Exp. 10/19; b) 091277A, Exp. 9/19.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1841-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1841-2019. Report a data issue: hello@regdatalab.com.